Study Says Byetta and Januvia Do Not Pose Extra Risk for Pancreatitis

The Medco/University of Texas study was designed to create an accurate positioning of the two drugs among the spectrum of diabetes medications when it comes to incidence of pancreatitis.

| Jul 8, 2010

A study released in late June has brought some welcome news to the makers of Byetta and Januvia: Users of the two diabetes drugs run no greater risk of developing pancreatitis than people with diabetes who take other drugs. In fact, both drugs seem to put users at slightly less risk for the condition.

Pancreatitis is an inflammation of the pancreas that can be extremely painful. In rare cases, it can lead to death. The study, conducted by Medco Health Solutions and the University of Texas Southwestern Medical School, found that people with diabetes already run twice the risk for acute pancreatitis as people who do not have diabetes.

Among those studied who were taking other diabetes medications, there were 5.72 cases of acute pancreatitis for every 1,000 patient years. The statistics for the Byetta and Januvia groups were, respectively, 5.69 and 5.54. (A fourth group, the control, took no diabetic medications at all.)

Byetta, the commercial name for exenatide, is co-manufactured by Amylin Pharmaceuticals and Eli Lilly & Co. Januvia, the commercial name for sitagliptin, is manufactured by Merck.

The FDA first raised concerns about Byetta in 2008 when it noted that 30 Byetta users had developed acute pancreatitis and that six of those patients later died. In 2009, the agency ordered a change in prescribing information for Januvia and Janumet in the wake of concerns about 88 users of the drug who has developed pancreatitis. (The FDA included Janumet, a combination of sitagliptin and metformin, because of its concerns that sitagliptin might be a causal factor in the pancreatitis.)

Both manufacturers strongly protested the FDA's methodology. In the case of Byetta, the statistical incidence of 30 cases of acute pancreatitis among 786,000 U.S. users was the equivalent to 1 in every 26,200 users. The six deaths from the condition were equivalent to 1 in every 131,000 users.

The Medco/University of Texas study was designed to create an accurate positioning of the two drugs among the spectrum of diabetes medications when it comes to incidence of pancreatitis. The researchers based their findings on observations derived from other studies. New Jersey-based Medco is a pharmacy benefit manager that runs its own chain of pharmacies and deals directly with about 20 percent of the U.S. population. The company lists Byetta and Januvia in its roster of preferred drugs.

(Editor's note: The author of this article, Patrick Totty, has been taking Byetta for almost two years as part of a clinical trial sponsored by a drug company that wishes to enter the U.S. market with a similar drug.)

* * *


No Pancreatitis Risk Seen in Byetta, Januvia Drugs

Click Here To View Or Post Comments

Categories: Byetta, Complications & Care, Diabetes, Diabetes, Januvia, Medications, Medications Research, Type 2 Issues

Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12th Annual Product Reference Guide
  • Insulin Syringe Chart
  • Insulin Pen Needles Chart
  • Fast-Acting Glucose
  • Sharps Disposal
  • Blood Glucose Meters Chart
  • Insulin Pumps Chart
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

Top Rated
Print | Email | Share | Comments (0)

You May Also Be Interested In...


Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.

When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.

For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.

Don't have your Diabetes Health Username? Register now and add your comments to all our content.

Have Your Say...

Username: Password:
©1991-2015 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.